OncoMatch/Clinical Trials/NCT05684731

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

Is NCT05684731 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including KM1 and Chemotherapy for ovarian cancer.

Phase 1RecruitingTongji HospitalNCT05684731Data as of May 2026

Treatment: KM1 · Chemotherapy — The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Adequate renal, hepatic, bone marrow function, adequate coagulation tests, adequate immune function by lymphocyte count.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify